Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Convertible Debt (2016 - 2021)

Historic Convertible Debt for Northwest Biotherapeutics (NWBO) over the last 12 years, with Q4 2021 value amounting to $300000.0.

  • Northwest Biotherapeutics' Convertible Debt changed 0.0% to $300000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $300000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $300000.0 for FY2021, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2021, Northwest Biotherapeutics' Convertible Debt is $300000.0, which was down 0.0% from $300000.0 recorded in Q4 2020.
  • Northwest Biotherapeutics' Convertible Debt's 5-year high stood at $6.6 million during Q1 2018, with a 5-year trough of $300000.0 in Q4 2020.
  • Over the past 4 years, Northwest Biotherapeutics' median Convertible Debt value was $5.1 million (recorded in 2017), while the average stood at $3.6 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first crashed by 4961.15% in 2017, then skyrocketed by 2026.75% in 2018.
  • Quarter analysis of 4 years shows Northwest Biotherapeutics' Convertible Debt stood at $6.0 million in 2017, then fell by 13.68% to $5.2 million in 2018, then tumbled by 94.22% to $300000.0 in 2020, then changed by 0.0% to $300000.0 in 2021.
  • Its Convertible Debt stands at $300000.0 for Q4 2021, versus $300000.0 for Q4 2020 and $315000.0 for Q3 2020.